Document:

Exhibit

Exhibit 10.5

CDK GLOBAL, INC. 2014 OMNIBUS AWARD PLAN
FORM OF PERFORMANCE STOCK UNIT AWARD AGREEMENT
CDK GLOBAL, INC. (the “Company”), pursuant to the 2014 Omnibus Award Plan (the “Plan”), hereby irrevocably grants you (“Participant”), on XXXX XX, 20__ (the “Grant Date”), a Performance Stock Unit Award (the “Award”) of forfeitable performance stock units of the Company (“PSUs”), each PSU representing the right to receive one share of the Company’s common stock, par value $0.01 per share (“Common Stock”), subject to the restrictions, terms and conditions herein.
WHEREAS, Participant has been selected as a participant in the three-year performance stock unit program of the Company covering the Company’s 20XX, 20XX and 20XX fiscal years, as described in the letter previously provided to Participant (the “PSU Award Letter”); and
WHEREAS, the Board of Directors of the Company has determined that it would be in the best interests of the Company and its stockholders to grant the award provided for herein to Participant, on the terms and conditions described in this Performance Stock Unit Award Agreement (this “Agreement”).
NOW, THEREFORE, for and in consideration of the promises and the covenants of the parties contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, for themselves, and their permitted successors and assigns, hereby agree as follows:
		
	1.
	Terms and Conditions.

		
	(a)
	Award.  Subject to the other terms and conditions contained in this Agreement, the actual number of PSUs that are earned, if any, pursuant to the terms and conditions of the Award will be determined by the Company (the “Total Award”) and shall be computed in accordance with Section 3 below, as a percentage of the sum of (i) the Target Number of PSUs set forth in the PSU Award Letter (the “Target Award”) plus (ii) any Dividend Equivalent PSUs (as defined below).  The Total Award shall be a whole number of PSUs only.

		
	(b)
	Performance Period.  Subject to the other terms and conditions contained in this Agreement, the performance period for the Award commenced on XXXX XX, 20XX and shall terminate on XXXX XX, 20XX (the “Performance Period”).

		
	(c)
	Dividend Equivalents.  Until shares of Common Stock are delivered to Participant in respect of the settlement of the Award, at no time shall Participant be deemed for any purpose to be the owner of shares of Common Stock in connection with the Award and Participant shall have no right to dividends in respect of the Award; provided, however, that each time the Company pays a dividend with respect to a share of Common Stock during the period from the Grant Date to the Payout Date (as defined below), Participant shall be credited with an additional number of PSUs (the “Dividend Equivalent PSUs”) equal to (i) the quotient obtained by dividing the amount of such dividend by the Fair Market Value (as defined in the Plan) of a share of Common Stock on such date, multiplied by (ii) the Total Award.

		
	(d)
	Settlement.  For Participants whose home country is the United States, subject to the other terms and conditions contained in this Agreement, the Company shall settle the Award by 

causing one share of Common Stock for each PSU in the Total Award that is outstanding (and not previously forfeited) as of the Payout Date to be registered in the name of Participant and held in book-entry form on the Payout Date.  For Participants whose home country is not the United States, subject to the other terms and conditions contained in this Agreement, the Company shall settle the Award by the payment to the Participant in cash (without interest) of an amount equal to the Fair Market Value of the PSUs (the U.S. dollar value of Participant’s PSUs will be converted into Participant’s local currency using the exchange rate determined by the Company) on the Payout Date subject to applicable withholding.
		
	2.
	Forfeiture of PSUs.

		
	(a)
	Termination of Employment Generally.  Except as otherwise determined by the Company in its sole discretion or as provided in Section 2(b) below, all PSUs and Dividend Equivalent PSUs shall be forfeited without consideration to Participant upon Participant’s termination of employment with the Company or its Affiliates for any reason (and Participant shall forfeit any rights to receive shares of Common Stock or cash in respect of the Award).

		
	(b)
	Termination After XXXX XX, 20XX due to Death, Disability or Retirement.  In the event that after the first anniversary of the commencement of the Performance Period and prior to completion of the Performance Period, Participant’s employment with the Company is terminated due to death, Disability (as defined in the Plan) or retirement (defined for purposes of this Agreement as voluntary termination of employment at or after age 65, or age 55 with 10 years of service with the Company or its Affiliates), Participant shall be entitled to receive a pro-rata portion of the Award determined in accordance with Section 3.  For the avoidance of doubt, if a Participant’s employment is terminated prior to XXXX XX, 20XX, the Award and any rights to receive shares of Common Stock, cash and Dividend Equivalent PSUs with respect thereto, will be forfeited without consideration.

		
	3.
	Performance Determinations.

		
	(a)
	Following completion of the Performance Period (or, if Participant’s employment has terminated after the first anniversary of the commencement of the Performance Period due to death, Disability, or retirement, as soon as administratively feasible (in the Committee’s sole discretion) following such termination), the Company will determine the Total Award, calculated as the number (rounded down to the nearest whole PSU) equal to the product of (i) the Target Award plus any Dividend Equivalent PSUs and (ii) the Final Payout Percentage; provided, that if Participant’s employment has terminated in the manner described in Section 2(b), the Total Award shall be calculated as the number (rounded down to the nearest whole PSU) equal to the product of (i) the Target Award plus any Dividend Equivalent PSUs, and (ii) the Pro-Rata Percentage.

		
	(b)
	In the event of a Change in Control:

		
	(i)
	if the Award is not continued, substituted or assumed (in accordance with Section 12 of the Plan) in a manner such that the securities underlying the Award following the Change in Control are traded on a “liquid market” (i.e., the Nasdaq Global Market, the New York Stock Exchange or a comparable international market in which the Participant is able to readily and without administrative complexity sell shares underlying the award, as reasonably determined by the Board) (a “Permitted Assumption”), then the Award shall become fully vested and the Payout Date shall be 

2

immediately prior to the Change in Control, with the Performance Goals deemed satisfied at the target level; or
		
	(ii)
	if the Award is subject to a Permitted Assumption in connection with the Change in Control, then the Performance Goals shall be deemed satisfied at the target level, and the service requirement shall continue in accordance with, and subject to, the terms of the award.

		
	(c)
	For purposes of this Agreement:

		
	(i)
	“Final Payout Percentage” is a number, expressed as a percentage, calculated by application of the Performance Formula to achievement of the Performance Goals over the Performance Period, as determined by the Committee.

		
	(ii)
	“Payout Date” shall be:

		
	•
	XXXX XX, 20XX or as soon as administratively feasible (but not later than 60 days) thereafter if Participant remains employed with the Company or its Affiliates until the end of the Performance Period;

		
	•
	XXXX XX, 20XX or as soon as administratively feasible (but not later than 60 days) thereafter if Participant’s employment with the Company and its Affiliates terminates due to retirement after the first anniversary of the commencement of the Performance Period; provided that if Participant subsequently dies or becomes Disabled during the Performance Period, the Payout Date shall be as soon as administratively feasible (but not later than 60 days) after Participant’s termination due to death or Disability;

		
	•
	as soon as administratively feasible (but not later than 60 days) after termination of employment if Participant’s employment with the Company and its Affiliates terminates due to death or Disability after the first anniversary of the commencement of the Performance Period; and

		
	•
	immediately prior to a Change in Control, if the Payment Date is accelerated pursuant to Section 3(b)(i) above.

		
	(iii)
	“Pro-Rata Percentage” is a number, expressed as a percentage, equal to the quotient of (i) the number of completed months from XXXX XX, 20XX until the date of Participant’s termination of employment, divided by (ii) 33.

		
	(d)
	All determinations with respect to the Award or this Agreement by the Company or Committee, including, without limitation, determinations of performance pursuant to the Performance Goals, the Final Payout Percentage, and timing of settlements, shall be within the Company’s absolute discretion and shall be final, binding and conclusive on Participant.

		
	4.
	Restrictive Covenant; Clawback; Incorporation by Reference.

		
	(a)
	Restrictive Covenant.  The effectiveness of the Award granted hereunder is conditioned upon the execution and delivery by Participant within ninety (90) days from the date of the Award of any restrictive covenant furnished herewith.  If the Company does not receive the signed 

3

(whether electronically or otherwise) restrictive covenant within such ninety (90) day period, the Award shall be terminable by the Company.
		
	(b)
	Clawback/Forfeiture.  Notwithstanding anything to the contrary contained herein, the PSUs may be forfeited without consideration if Participant, as determined by the Committee in its sole discretion (i) engages in an activity that is in conflict with or adverse to the interests of the Company or any Affiliate, including but not limited to fraud or conduct contributing to any financial restatements or irregularities, or (ii) without the consent of the Company, while employed by or providing services to the Company or any Affiliate or after termination of such employment or service, violates a non-competition, non-solicitation or non-disclosure covenant or agreement between Participant and the Company or any Affiliate.  If Participant engages in any activity referred to in the preceding sentence, Participant shall, at the sole discretion of the Committee, forfeit any gain realized in respect of the PSUs (which gain shall be deemed to be an amount equal to the Fair Market Value, on the applicable Payout Date, of the shares of Common Stock or cash delivered to Participant under this Award), and repay such gain to the Company.

		
	(c)
	Incorporation by Reference, Etc.  The provisions of the Plan are hereby incorporated herein by reference.  Except as otherwise expressly set forth herein, this Agreement shall be construed in accordance with the provisions of the Plan, and any capitalized terms not otherwise defined in this Agreement shall have the definitions set forth in the Plan.

		
	5.
	Compliance with Legal Requirements; Stockholder Approval.  The granting and delivery of the Award, and any other obligations of the Company under this Agreement, shall be subject to all applicable federal, state, local and foreign laws, rules and regulations and to such approvals by any regulatory or governmental agency as may be required. Notwithstanding anything herein to the contrary, the Award shall be contingent upon the approval of the Plan by the Company’s stockholders at the 2015 annual meeting of stockholders, and shall be null and void if such approval is not obtained.

		
	6.
	Transferability.  No PSUs may be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by a Participant other than by will or by the laws of descent and distribution and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or an Affiliate.

		
	7.
	Miscellaneous.

		
	(a)
	No Other Rights as a Stockholder.  Except as set forth herein, the Participant shall not have any rights as the owner of any shares of Common Stock subject to the PSUs until any such shares are delivered to the Participant upon settlement of the PSUs.

		
	(b)
	Waiver.  Any right of the Company contained in this Agreement may be waived in writing by the Committee.  No waiver of any right hereunder by any party shall operate as a waiver of any other right, or as a waiver of the same right with respect to any subsequent occasion for its exercise, or as a waiver of any right to damages.  No waiver by any party of any breach of this Agreement shall be held to constitute a waiver of any other breach or a waiver of the continuation of the same breach.

		
	(c)
	Severability.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law.

4

		
	(d)
	No Right to Employment.  Nothing contained in this Agreement shall be construed as giving Participant any right to be retained, in any position, as an employee, consultant or director of the Company or its Affiliates or shall interfere with or restrict in any way the right of the Company or its Affiliates, which are hereby expressly reserved, to remove, terminate or discharge Participant with or without cause at any time for any reason whatsoever.  Although over the course of employment terms and conditions of employment may change, the at-will term of employment will not change.

		
	(e)
	Successors.  The terms of this Agreement shall be binding upon and inure to the benefit of the Company, its successors and assigns, Participant and Participant’s beneficiaries, executors, administrators, heirs and successors.

		
	(f)
	Entire Agreement.  This Agreement and the Plan contain the entire agreement and understanding of the parties hereto with respect to the subject matter contained herein and supersede all prior communications, representations and negotiations in respect thereto.  No change, modification or waiver of any provision of this Agreement shall be valid unless the same be in writing and signed by the parties hereto, except for any changes permitted without consent of Participant under the Plan.

		
	(g)
	Governing Law.  This Agreement shall be construed and interpreted in accordance with the laws of the State of Delaware without regard to principles of conflicts of law thereof, or principles of conflicts of laws of any other jurisdiction which could cause the application of the laws of any jurisdiction other than the State of Delaware.

		
	(h)
	Headings.  The headings of the Sections hereof are provided for convenience only and are not to serve as a basis for interpretation or construction, and shall not constitute a part, of this Agreement.

	
			
	CDK GLOBAL, INC.
	 
	 

	 
	 
	 

	Lee J. Brunz
	 
	 

	Vice President, General Counsel and Secretary
	 
	 

	 
	 
	 

	Signature
	 
	Date

	 
	 
	 

	Print Name

	 
	 
	 

	 
	 
	 

5Exhibit 10.1

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

This Employment Agreement
(the “Agreement”), made and entered into this 21st day of September, 2015 by and between Akari Therapeutics
PLC, a company organizaed under the law of England and Wales
(the “Company”), and Gur Roshwalb (“Executive”).

 

WHEREAS, the
Executive and the Company are currently parties to an Executive Service Agreement dated March 4, 2013 (the “Prior Agreement”);

 

WHEREAS, the
Company anticipates entering into a Share Exchange Agreement
(the “Exchange Agreement”) relating to the acquisition of
Volution Immuno Pharmaceuticals SA pursuant to which the Company will survive the transaction and the Executive will
continue to be employed by the Company (the “Transaction”); and

 

WHEREAS, Company
and the Executive wish to enter into this Agreement in connection with the Transaction effective as of the Date of Completion (as
such term is defined in the Exchange Agreement) at which time this Agreement will supersede and replace in its entirety the Prior
Agreement, and the Prior Agreement shall be of no further force or effect;

 

NOW, THEREFORE,
in consideration of the mutual promises, terms, provisions, and conditions contained herein, the parties agree as follows:

 

1.          Roles
and Duties. 

 

(a)         Chief
Executive Officer Role. Subject to the terms and conditions of this Agreement, Company shall continue to employ Executive as
its Chief Executive Officer reporting to Company’s Board of Directors (“Board”). Executive accepts such employment
upon the terms and conditions set forth herein, and agrees to perform to the best of Executive’s ability the duties normally
associated with such position and as determined by Company in its sole discretion. During Executive’s employment, Executive
shall devote all of Executive’s business time and energies to the business and affairs of Company, provided
that nothing contained in this Section 1 shall prevent or limit Executive’s right to manage Executive’s personal investments
on Executive’s own personal time, including, without limitation the right to make passive investments in the securities of:
(a) any entity which Executive does not control, directly or indirectly, and which does not compete with Company, or (b) any publicly
held entity so long as Executive’s aggregate direct and indirect interest does not exceed two percent (2%) of the issued
and outstanding securities of any class of securities of such publicly held entity. During Executive’s employment, Executive shall not engage in any other non-Company related business activities of any nature whatsoever
(including board memberships) without the Company’s prior written consent,. In addition, and so long as such activities
do not interfere materially with Executive’s performance of Executive’s duties hereunder, Executive also may participate
in civic, charitable and
professional activities, but shall not serve in any official capacity, including as a member of a board, without the
prior written consent of the Company’s Board.

 

    1

     

    

 

(b)         Board
Membership. Executive shall serve as a member of the Board, during Executive’s employment hereunder, subject to any required
approval. Executive’s service as a Board member shall be without further compensation. Executive shall resign from the Board
effective immediately upon the termination of Executive’s employment with Company for any reason. 

 

2.          Term
of Employment.

 

(a)         Term.
The term of this Agreement shall commence on the Closing Date (the “Commencement Date”) and shall continue for a period
of one year (the “Term”), unless terminated earlier pursuant to Section 2(b). The Term shall renew automatically for
successive one-year periods, unless either party has given written notice three-months prior to the expiration of the Term that
such party elects not to renew the Term. In the event of non-renewal, this Agreement and the Executive’s employment hereunder
shall terminate automatically at the close of business on the last day of the Term.

 

(b)         Termination.
Notwithstanding anything else contained in this Agreement, Executive’s employment hereunder shall terminate prior to the
end of the Term upon the earliest to occur of the following:

 

(i)         Death.
Immediately upon Executive’s death;

 

(ii)        Termination
by Company.

 

(A)        If
because of Executive’s Disability (as defined below in Section 2(c)), written notice by Company to Executive that Executive’s
employment is being terminated as a result of Executive’s Disability, which termination shall be effective on the date of
such notice or such later date as specified in writing by Company;

 

(B)         If
for Cause (as defined below in Section 2(d)), written notice by Company to Executive that Executive’s employment is being
terminated for Cause which termination shall be effective on the date of such notice or such later date as specified in writing
by Company; or

 

(C)         If
by Company for reasons other than under Sections 2(b)(ii)(A) or (B), written notice by Company to Executive that Executive’s
employment is being terminated, which termination shall be effective thirty (30) days after the date of such notice or
such later date as specified in writing by Company.

 

(iii)         Termination
by Executive.

 

    2

     

    

 

(A)         If
for Good Reason (as defined below in Section 2(e)), written notice by Executive to Company that Executive is terminating Executive’s
employment for Good Reason and that sets forth the factual basis supporting the alleged Good Reason, which termination shall be
effective thirty (30) days after the date of such notice; provided that if Company has cured the circumstances giving rise
to the Good Reason, then such termination shall not be effective; or

 

(B)         If
without Good Reason, written notice by Executive to Company that Executive is terminating Executive’s employment, which termination
shall be effective at least thirty (30) days after the date of such notice.

 

Notwithstanding anything
in this Section 2(b), Company may at any point terminate Executive’s employment for Cause prior to the effective date of
any other termination contemplated hereunder.

 

(c)         Definition
of “Disability”. For purposes of this Agreement, “Disability” shall mean Executive’s incapacity
or inability to perform Executive’s duties and responsibilities as contemplated herein for one hundred twenty (120) days
or more within any one (1) year period (cumulative or consecutive), because Executive’s physical or mental health has become
so impaired as to make it impossible or impractical for Executive to perform the duties and responsibilities contemplated hereunder.
Determination of Executive’s physical or mental health shall be determined by Company after consultation with a medical expert
appointed by mutual agreement between Company and Executive who has examined Executive. Executive hereby consents to such examination
and consultation regarding Executive’s health and ability to perform as aforesaid.

 

(d)         Definition
of “Cause”. Cause” shall include: (i) Executive’s willful engagement in dishonesty, illegal conduct
or gross misconduct, which is, in each case, is materially injurious to Company or any affiliate; (ii) Executive’s deliberate
insubordination; (iii) Executive’s substantial malfeasance or nonfeasance of duty; (iv) Executive’s unauthorized disclosure
of confidential information; (v) Executive’s embezzlement, misappropriation or fraud, whether or not related Executive’s
employment with Company; or (vi) Executive’s breach of a material provision of any employment, non-disclosure, invention
assignment, non-competition, or similar agreement between Executive and Company. In all cases, Company shall provide Executive
with written notice of the specific conduct or events that Company believes constitutes Cause and, in case of (ii) and (iii) above,
Executive shall have thirty (30) days to effect a cure of the claimed conduct or events.

 

    3

     

    

 

(e)         Definition
of “Good Reason”. As used herein, a “Good Reason” shall mean: (i) relocation
of Executive’s principal business location to a location
more than fifty (50) miles from Executive’s then-current business location;
(ii) a material diminution in Executive’s duties, authority
or responsibilities; or (iii) a material reduction in the Executive’s
Base Salary; provided that (A) Executive provides Company with written
notice that Executive intends to terminate Executive’s employment hereunder for one of the grounds set forth in this Section
2(e) within fifteen (15) days of such ground occurring, (B) if such ground is capable of being cured, the Company has failed to
cure such ground within a period of thirty (30) days from the date of such written notice, and (C) Executive terminates Executive’s
employment within sixty (60) days from the date of notice. For purposes of clarification, the above-listed conditions shall apply
separately to each occurrence of Good Reason and failure to adhere to such conditions in the event of Good Reason shall not disqualify
Executive from asserting Good Reason for any subsequent occurrence of Good Reason. For purposes of this Agreement, “Good
Reason” shall be interpreted in a manner, and limited to the extent necessary, so that it shall not cause adverse tax consequences
for either party with respect to Section 409A (“Section 409A”) of the Internal Revenue Code of 1986, as amended (the
“Code”) and any successor statute, regulation and guidance thereto.

 

3.          Compensation.

 

(a)         Base
Salary. Company shall pay Executive a base salary (the “Base Salary”) at the annual rate of $375,000. The Base
Salary shall be payable in substantially equal periodic installments in accordance with Company’s payroll practices as in
effect from time to time. Company shall deduct from each such installment all amounts required to be deducted or withheld under
applicable law or under any employee benefit plan in which Executive participates. The Board or an appropriate committee thereof
shall review the Base Salary on an annual basis.

 

(b)         Annual
Performance Bonus. Executive shall be eligible to receive an annual cash bonus (the “Annual Performance Bonus”),
with the target amount of such Annual Performance Bonus equal to forty percent (40%) of Executive’s Base Salary in the year
to which the Annual Performance Bonus relates, provided that the actual amount of the Annual Performance Bonus may be greater
or less than such target amount. The amount of the Annual Performance Bonus shall be determined by the Board or an appropriate
committee thereof in its sole discretion, and shall be paid to Executive no later than January 31st of the calendar
year immediately following the calendar year in which it was earned. Except as otherwise provided for in this Agreement, Executive
must be employed by Company on the date on which the Annual Performance
Bonus is paid in order to be eligible for, and to be deemed as having earned, such Annual Performance Bonus. Company shall deduct
from the Annual Performance Bonus all amounts required to be deducted or withheld under applicable law or under any employee benefit
plan in which Executive participates.

 

    4

     

    

 

(c)         Equity.
Subject to approval of the Board or an appropriate committee thereof, Company shall grant Executive on the Commencement Date or
as soon as practicable thereafter pursuant to the terms of the Celsus Therapeutics PLC 2014 Equity Incentive Plan (the “Plan”),
a stock option (the “Option”) to purchase 32,543,700 shares of common stock of the Company, at a per share exercise
price equal to the Fair Market Value (as defined in the Plan) of the Company’s common stock on the date of grant, which Option
shall be, to the maximum extent permissible, treated as an “incentive stock option” within the meaning of Section 422
of the Code. The Option shall vest ratably on a semi-annual basis over four (4) years on each anniversary of the Commencement Date,
provided that Executive remains employed by Company on the vesting date; provided, further, that there is
a minimum 25% vesting and, however, that the Option shall vest fully immediate prior to a Change of Control (as defined below)
or upon the non-renewal of this Agreement. The Option shall be evidenced in writing by, and subject to the terms and conditions
of, the Plan and the Company’s standard form of stock option agreement, which agreement shall expire ten (10) years from
the date of grant except as otherwise provided in the stock option agreement or the Plan.

 

(d)         Paid
Time Off. Executive may take up to four (4) weeks of paid time off (“PTO”) per year, to be scheduled to minimize
disruption to Company’s operations, pursuant to the terms and conditions of Company policy and practices as applied to Company
senior executives.

 

(e)         Fringe
Benefits. Executive shall be entitled to participate in all benefit/welfare plans and fringe benefits provided to Company senior
executives. Executive understands that, except when prohibited by applicable law, Company’s benefit plans and fringe benefits
may be amended by Company from time to time in its sole discretion.

 

(f)         Professional
Associations. The Company will pay Executive’s annual membership fees associated with his membership in the American
College of Physicians.

 

(g)         Reimbursement
of Expenses. Company shall reimburse Executive for all ordinary and reasonable out-of-pocket business expenses incurred by
Executive in furtherance of Company’s business in accordance with Company’s policies with respect thereto as in effect
from time to time. Executive must submit any request for reimbursement no later than
ninety (90) days following the date that such business expense is incurred. All reimbursements provided under this Agreement
shall be made or provided in accordance with the requirements of Section 409A including, where applicable, the requirement that
(i) any reimbursement is for expenses incurred during Executive’s lifetime (or during a shorter period of time specified
in this Agreement); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible
for reimbursement in any other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last
day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits
is not subject to liquidation or exchange for another benefit.

 

(h)         Indemnification.
Executive shall be entitled to indemnification with respect to Executive’s services provided hereunder pursuant to English
law, the terms and conditions of Company’s articles of incorporation, Company’s directors and officers (“D&O”)
liability insurance policy and Company’s standard indemnification agreement for directors and officers as executed by Company
and Executive.

 

    5

     

    

 

4.          Payments
Upon Termination.

 

(a)         Definition
of Accrued Obligations. For purposes of this Agreement, “Accrued Obligations” means: (i) the portion of Executive’s
Base Salary that has accrued, including vacation time, prior to any termination of Executive’s employment with Company and
has not yet been paid; and (ii) the amount of any expenses properly incurred by Executive on behalf of Company prior to any such
termination and not yet reimbursed. Executive’s entitlement to any other compensation or benefit under any plan of
Company shall be governed by and determined in accordance with the terms of such plans, except as otherwise specified in this Agreement.

 

(b)         Termination
by Company for Cause, by Executive Without Good Reason, or as a Result of Executive’s Disability or Death. If Executive’s
employment hereunder is terminated by Company for Cause, by Executive without Good Reason, as a result of Executive’s Disability
or death, then Company shall pay the Accrued Obligations to Executive promptly following the effective date of such termination
and shall have no further obligations to Executive.

 

(c)         Termination
by Company Without Cause, by Executive For Good Reason or Upon Expiration of the Term. In the event that Executive’s
employment is terminated by action of Company other than for Cause, Executive terminates Executive’s employment for Good
Reason or due to non-renewal of the Term, then, in addition to the Accrued Obligations, Executive shall receive the following,
subject to the terms and conditions described in Section 4(e) (including Executive’s execution of a release of claims):

 

(i)         Severance
Payments. An amount equal to the sum of (x) Executive’s annual Base Salary at the rate in effect as of the termination
date, and (y) the greater of actual or target Annual Performance Bonus to which Executive may have been entitled for the year
in which Executive’s employment terminates, in each case less all customary and required taxes and employment-related deductions;
provided that this bonus payment shall not be made in the event the termination is solely due to non-renewal of the Term the Company.
The severance payment provided for in this Section 4(c)(i) shall be paid over a 12-month period in accordance with Company’s
normal payroll practices (provided such payments shall be made at least monthly), commencing on the first payroll date following
the date on which the release of claims required by Section 4(e) becomes effective and non-revocable, but not after sixty (60)
days following the effective date of termination from employment; provided, that if the 60th day falls in the
calendar year following the year during which the termination or separation from service occurred, then the payments will commence
in such subsequent calendar year; provided, further that if such payments commence in such subsequent year, the
first such installment shall include an amount equal to the payments that would have been paid if the payments had commenced in
the first month following the termination of employment.

 

    6

     

    

 

(ii)         Benefits
Payments. The Company shall pay to Executive an amount equal to the Company’s share of the premium paid for Executive
while Executive was an active employee for medical insurance coverage under the Company’s health care plan (the “Healthcare
Subsidy”) for a period of twelve (12) months following Executive’s termination date. The Healthcare Subsidy shall be
paid, less required withholdings, in the same manner and the same time as the payments under Section 4(c)(i) are paid.

 

Payment of the above
described severance payments and benefits are expressly conditioned on Executive’s execution without revocation of the release
of claims under Section 4(e) and return of Company property under Section 6
and continued compliance with the Executive’s obligations in the Restrictive Covenant Agreement (as defined below). In the
event that Executive is eligible for the severance payments and benefits under this Section 4(c), Executive shall not be eligible
for and shall not receive any of the severance payments and benefits as provided in Section 4(d).

 

(d)         Termination
by Company Without Cause or by Executive For Good Reason Following a Change of Control. In the event that a Change of Control (as
defined below) occurs and within a period of one (1) year following the Change of Control, either Executive’s employment
is terminated other than for Cause, or Executive terminates Executive’s employment for Good Reason, then, in addition
to the Accrued Obligations, Executive shall receive the following, subject to the terms and conditions described in Section 4(e)
(including Executive’s execution of a release of claims):

 

(i)         Severance
Payment. An amount equal to one and a half times the sum of (x) Executive’s annual Base Salary at the rate in effect
as of the termination date, and (y) the target Annual Performance Bonus to which Executive may have been entitled for the year
in which Executive’s employment terminates, in each case less all customary and required taxes and employment-related deductions.
The severance payment provided for in this Section 4(d)(i) shall be paid over a 18-month period in accordance with Company’s
normal payroll practices (provided such payments shall be made at least monthly), commencing on the first payroll date following
the date on which the release of claims required by Section 4(e) becomes effective and non-revocable, but not after sixty (60)
days following the effective date of termination from employment; provided, that if the 60th day falls in the calendar
year following the year during which the termination or separation from service occurred, then the payments will commence in such
subsequent calendar year; provided further that if such payments commence in such subsequent year, the first such installment
shall include an amount equal to the payments that would have been paid if the payments had commenced in the first month following
the termination of employment.

 

    7

     

    

 

(ii)         Benefit
Payments. The Company shall pay to Executive the Healthcare Subsidy for a period of eighteen (18) months following Executive’s
termination date. The Healthcare Subsidy shall be paid, less required withholdings, in the same manner and the same time as the
payments under Section 4(d)(i) are paid.

 

Payment of the above
described severance payments and benefits are expressly conditioned on Executive’s execution without revocation of the release
of claims under Section 4(e) and return of Company property under Section 6 and continued compliance with Executive’s obligations
in the Restrictive Covenant Agreement. In the event that Executive is
eligible for the severance payments and benefits under this Section 4(d), Executive shall not be eligible for and shall not receive
any of the severance payments and benefits as provided in Section 4(c).

 

As
used herein, a “Change of Control” shall mean the occurrence of any of the following events: (A) The approval
by shareholders of the Company of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation
which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either
by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of
the total voting power represented by the voting securities of the Company or such surviving entity outstanding immediately after
such merger or consolidation; or (B) The approval by the shareholders of the Company of a plan of complete liquidation of the Company
or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets.
except if company’s valuation is less then that at the time of the merger on the 16th September 2015, as calculated
including any prior distribution of funds, dividends or sales proceeds

 

(e)         Execution
of Release of Claims. Company shall not be obligated to pay Executive any of the severance payments or benefits described in
this Section 4 unless and until Executive has executed (without revocation) a timely release of claims in a form that is acceptable
to Company, and which includes standard and reasonable terms regarding items such as mutual non-disparagement, confidentiality,
cooperation and the like, which must be provided to Executive within fifteen (15) days following separation from service, and must
be effective and irrevocable prior to the 60th day following Executive’s separation from service (the “Review
Period”), and which shall include a general release of claims against Company and its affiliated entities and each of their
officers, directors, employees and others associated with Company and its affiliated entities. If Executive fails or refuses to return
such agreement, or revokes the agreement, within the Review Period, Executive’s severance payments hereunder and benefits
shall be forfeited.

 

(f)         No
Other Payments or Benefits Owing. The payments and benefits set forth in this Section 4 shall be the sole amounts owing to
Executive upon termination of Executive’s employment for the reasons set forth above and Executive shall not be eligible
for any other payments or other forms of compensation or benefits. The payments and benefits set forth in Section 4 shall be the
sole remedy, if any, available to Executive in the event that Executive brings any claim against Company relating to the termination
of Executive’s employment under this Agreement.

 

    8

     

    

 

5.          Prohibited
Competition And Solicitation. Executive expressly acknowledges that: (a) there are competitive and proprietary aspects of the business
of Company; (b) during the course of Executive’s employment, Company shall furnish, disclose or make available to Executive
confidential and proprietary information and may provide Executive with unique and specialized training; (c) such Confidential
Information and training have been developed and shall be developed by Company through the expenditure of substantial time, effort
and money, and could be used by Executive to compete with Company; and (d) in the course of Executive’s employment, Executive
shall be introduced to customers and others with important relationships to Company, and any and all “goodwill” created
through such introductions belongs exclusively to Company, including, but not limited to, any goodwill created as a result of direct
or indirect contacts or relationships between Executive and any customers of Company. In light of the foregoing acknowledgements
and as a condition of employment hereunder, Executive agrees to execute and abide by Company’s Confidentiality, Intellectual
Property, Non-Competition and Non-Solicitation Agreement (the “Restrictive Covenant Agreement”).

 

6.          Property
and Records. Upon the termination of Executive’s employment hereunder for any reason or for no reason, or if Company otherwise
requests, Executive shall: (a) return to Company all tangible business information and copies thereof (regardless how such Confidential
Information or copies are maintained), and (b) deliver to Company any property of Company which may be in Executive’s possession,
including, but not limited to, Blackberry-type devices, smart phones, laptops, cell phones, products, materials, memoranda, notes,
records, reports or other documents or photocopies of the same.

 

7.          Code
Sections 409A and 280G. 

 

(a)         In
the event that the payments or benefits set forth in Section 4 of this Agreement constitute “non-qualified deferred compensation”
subject to Section 409A, then the following conditions apply to such payments or benefits:

 

(i)         Any
termination of Executive’s employment triggering payment of benefits under Section 4 must constitute a “separation
from service” under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits
can commence. To the extent that the termination of Executive’s employment does not constitute a separation of service under
Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated
to be provided by Executive to Company at the time Executive’s employment terminates), any such payments under Section 4
that constitute deferred compensation under Section 409A shall be delayed until after the date of a subsequent event constituting
a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h). For purposes of clarification,
this Section 7(a) shall not cause any forfeiture of benefits on Executive’s part, but shall only act as a delay until such
time as a “separation from service” occurs.

 

    9

     

    

 

(ii)         Notwithstanding
any other provision with respect to the timing of payments under Section 4 if, at the time of Executive’s termination, Executive
is deemed to be a “specified employee” of Company (within the meaning of Section 409A(a)(2)(B)(i) of the Code), then
limited only to the extent necessary to comply with the requirements of Section 409A, any payments to which Executive may become
entitled under Section 4 which are subject to Section 409A (and not otherwise exempt from its application) shall be withheld until
the first (1st) business day of the seventh (7th) month following the termination of Executive’s employment,
at which time Executive shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to Executive
under the terms of Section 4.

 

(b)         It
is intended that each installment of the payments and benefits provided under Section 4 of this Agreement shall be treated as a
separate “payment” for purposes of Section 409A. Neither Company nor Executive shall have the right to accelerate or
defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.

 

(c)         Notwithstanding
any other provision of this Agreement to the contrary, this Agreement shall be interpreted and at all times administered in a manner
that avoids the inclusion of compensation in income under Section 409A, or the payment of increased taxes, excise taxes or other
penalties under Section 409A. The parties intend this Agreement to be in compliance with Section 409A. Executive acknowledges and
agrees that Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under
this Agreement, including but not limited to consequences related to Section 409A.

 

(d)         If
any payment or benefit Executive would receive under this Agreement, when combined with any other payment or benefit Executive
receives pursuant to a Change of Control (for purposes of this section, a “Payment”) would: (i) constitute a “parachute
payment” within the meaning of Section 280G the Code; and (ii) but for this sentence, be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either: (A) the full amount of such Payment;
or (B) such lesser amount (with cash payments being reduced before stock option compensation) as would result in no portion of
the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state
and local employments taxes, income taxes, and the Excise Tax, results in Executive’s receipt, on an after-tax basis, of
the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.

 

    10

     

    

 

8.          General.

 

(a)         Notices.
Except as otherwise specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall
be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight
courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic
transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt.

 

Notices to Executive
shall be sent to the last known address in Company’s records or such other address as Executive may specify in writing.

 

Notices to Company
shall be sent to:

 

24 West 40th Street,
8th Floor

Attention: Chairman of the Board

 

or to such other Company representative
as Company may specify in writing.

 

(b)         Modifications
and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by
the parties hereto.

 

(c)         Waivers
and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only
by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall
be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether
or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was
given, and shall not constitute a continuing waiver or consent.

 

(d)         Assignment.
Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of Company’s
business or that aspect of Company’s business in which Executive is principally involved. Executive may not assign Executive’s
rights and obligations under this Agreement without the prior written consent of Company.

 

    11

     

    

 

(e)         Governing
Law/Dispute Resolution. This Agreement and the rights and obligations of
the parties hereunder shall be construed in accordance with and governed by the law of the State of New York, without giving effect
to the conflict of law principles thereof. Any legal action or proceeding with respect to this Agreement shall be brought in the
courts of the Supreme Court of the State of New York, New York County, or of the United States of America for the Southern District
of New York. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property,
generally and unconditionally, the non-exclusive jurisdiction of the aforesaid
courts.

 

(f)         Jury
Waiver. ANY, ACTION, DEMAND, CLAIM, OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT SHALL BE RESOLVED BY A JUDGE
ALONE AND EACH OF COMPANY AND EXECUTIVE WIAVES ANY RIGHT TO A JURY TRIAL THEREOF.

 

(g)         Headings
and Captions. The headings and captions of the various subdivisions of this Agreement are for convenience of reference only
and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

(h)         Entire
Agreement. This Agreement, together with the other agreements specifically referenced herein, embodies the entire agreement
and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written
agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement
of any kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms
and provisions of this Agreement.

 

(i)         Counterparts.
This Agreement may be executed in two or more counterparts, and by different parties hereto on separate counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. For all purposes a signature
by fax shall be treated as an original.

 

[Signature Page to Follow]

 

    12

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the date first written above.

 

	GUR ROSHWALB	 	CELSUS THERAPEUTICS PLC
	 	 	 
	/s/Gur Roshwalb	 	By: 	/s/ Ray Prudo
	Signature	 	 	Name: Ray Prudo
	
        Address:
	 	 	
        Title: Executive Chairman

 

    13

     

    

 

Appendix A

 

Confidentiality, Intellectual Property,
Non-Competition and Non-Solicitation Agreement

 

This Confidentiality, Intellectual Property,
Non-Competition and Non-Solicitation Agreement (the “Agreement”) is entered into as of _______, 2015,
by and between Celsus Therapeutics PLC (the “Company”), and Gur Roshwalb, an individual (the “Executive”).

 

RECITALS

 

WHEREAS, concurrently
upon the execution of this Agreement, the Company and Executive are entering into that certain Executive Employment Agreement under
which Executive shall continue to be employed by the Company; and

 

WHEREAS Executive
acknowledges that: (i) there are competitive and proprietary aspects of the business of Company; (ii) during the course of Executive’s
employment, Company has furnished, disclosed and/or made available and shall furnish, disclose and/or make available to Executive
confidential and proprietary information and may have provided and may provide Executive with unique and specialized training;
(iii) such Confidential Information and training have been developed and shall be developed by Company through the expenditure
of substantial time, effort and money, and could be used by Executive to compete with Company; and (iv) in the course of Executive’s
employment, Executive was introduced and shall be introduced to customers and others with important relationships to Company,
and any and all “goodwill” created through such introductions belongs exclusively to Company, including, but not limited
to, any goodwill created as a result of direct or indirect contacts or relationships between Executive and any customers of Company;
and

 

WHEREAS, in light of the foregoing
acknowledgements the Company requires that Executive make certain proprietary information, invention assignment, non-compete and
non-solicitation commitments as a condition to the continuation of his employment;

 

THEREFORE, in
consideration of Executive’s continued employment with the Company, and the compensation received by Executive from the Company,
from time to time, Executive and Company hereby agree as follows:

 

1.   Definitions. For purposes of this
Agreement, the following terms are defined as follows:

 

1.1.          “Affiliate”
of the Company means an entity that, directly or indirectly, controls, is controlled by, or is under common control with the Company.

 

    14

     

    

 

1.2.          "Company
Intellectual Property" means Intellectual Property Rights created, conceived, conducted, developed, reduced to practice,
compiled, written, authored, made and/or produced by Executive (whether jointly or alone), whether prior to or during the course
of Executive employment with the Company, whether or not during working hours, and/or conceived, conducted, developed, reduced
to practice, compiled, written, authored, made and/or produced by Executive, prior to, during the term of Executive's employment
or thereafter using Company's premises, intellectual property (including without limitation Company Intellectual Property) materials,
products, and/or resources, all whether or not recorded in material form.

 

1.3.          “Confidential
Information” any and all information, data, materials, Know-How and Documents in whatever form, including but not
limited to technical and scientific information, data, information regarding research and development related to actual or anticipated
products, laboratory records, analytical and quality control data, trial data, case report forms, data analyses, reports or summaries
and information contained in submissions to, and information from regulatory authorities', inventions, whether patentable or non-patentable,
discoveries, conceptions, intellectual property rights, data rights, records, results, formulations, methods, processes, techniques,
compilation, program, devices, systems, compounds, innovations, designs, drawings, sketches, diagrams, formulas, computer files,
product definitions, product research, manuals, selection processes, data, methods of manufacture, planning processes, trade secrets,
business secrets, business plans, copyrights, proprietary information, customer lists, names of customers, list of suppliers, marketing
plans, strategies, forecasts, business forecasts, processes, finances, costing, sales, prices, terms of payment, details of employees
and officers and of the remuneration and other benefits paid to them, improvements and any other data related to the business or
affairs of Company, its Affiliates and/or their respective customers, including customers with whom Company is negotiating, which
is: (i) disclosed by or on behalf of Company, Affiliates and/or their respective customers to Executive; (ii) was or may be otherwise
acquired by Executive during his employment with the Company; and/or (iii) was and/or may be generated and/or developed by Executive
as a result of: (a) use by Executive of any Confidential Information of the Company, its Affiliates and/or their respective customers;
and/or (b) Executive's employment by Company, all whether or not in the case of documents or other written materials or any materials
in electronic format they are or were marked as confidential and whether or not, in the case of other information, such information
is identified or treated by the Company or any of its Affiliates as being confidential.

 

1.4.          "Documents"
means documents, records, notebooks, results, agreements, calculations in each case whether electronic or in hard copy.

 

    15

     

    

 

1.5.          “Inventions”
means all Know-How, Documents and business methods, inventions, discoveries, formulas, ideas, results, records, concepts, processes,
techniques, developments, improvements, innovations, new uses, derivatives, processes, procedures formulae, models, assays prototypes,
methods, designs, techniques, compounds, conceptions, results, data, data rights, know how, materials, records, documentation,
technology, products, works of authorship, laboratory records, analytical and quality control data, trial data, case report forms,
data analyses, reports or summaries, all whether or not patentable, copyrightable or capable of registration, and whether or not
recorded in any medium.

 

1.6.          "Intellectual
Property Rights" means patents, Inventions, copyright and related rights, trade marks, trade names, service marks
and domain names, rights in get-up, goodwill, rights to sue for passing off, design rights, semi-conductor topography rights, database
rights, confidential information, moral rights, proprietary rights, data rights, enforcement rights, royalty rights and any other
intellectual property rights in each case whether registered or unregistered and including all applications or rights to apply
for, and renewals or extensions of such rights and all similar or equivalent rights or forms of protection which subsist or will
subsist now or in the future in any part of the world.

 

1.7.          "Know
How" means a package of expertise, practical information or skills, resulting from experience and testing relating
to any inventions, formulae, designs, drawings, procedures or methods.

 

2.   Confidential Information.
Executive hereby covenants and undertakes as follows:

 

2.1.          Nondisclosure
of Confidential Information.  Executive shall not at any time during his employment nor at any time after its termination
except for the benefit of the Company or its Affiliates, directly or indirectly use or assist a third party to use; divulge, disclose,
publish, transfer or communicate; and/or permit or cause any unauthorized disclosure of any Confidential Information relating to
the Company, its Affiliates, and/or their respective customers, prospective customers or suppliers. Notwithstanding
any other provision of this agreement, Executive may communicate with the government about possible legal violations without violating
the provisions of the Agreement.

 

2.2.          The
restrictions in clause do not apply to:

 

2.2.1.          any
disclosure required for the proper performance of the Executive's duties during his employment or as authorized by the Company's
Board of Directors;

 

2.2.2.          any
disclosure made to any person authorized by the Company to possess the relevant information;

 

2.2.3.          any
information or knowledge that was known to the Executive prior to the commencement date of his employment; or

 

2.2.4.          any
information which becomes available to the public generally otherwise than through the default of the Executive.

 

    16

     

    

 

2.3.          Any
and all Confidential Information, Documents and Company Intellectual Property including, without limitation, lists of customers
and suppliers, employees correspondence, documents, computer and other discs and tapes, data listings, codes, designs and drawings
and other documents and materials whatsoever in Executive's possession or under Executive's control and whether or not made or
created by Executive, relating to the business and/or the financial affairs of the Company, its Affiliates, and/or their respective
agents, customers, prospective customers and/or suppliers, are and shall remain the exclusive property of the Company or its relevant
Affiliate; will be handed over by Executive to the Company on demand and, in any event, immediately on the termination of Executive's
employment and Executive will certify that all such property has been so handed over; and will on demand and, in any event, immediately
on the termination of Executive's employment, will be permanently deleted from any computer system in Executive's possession or
under Executive's control.

 

3.   Intellectual
Property

 

3.1.          The
parties acknowledge that Executive may have created in the past and/or may create in the future Inventions (alone or jointly),
prior to, during the course of Executive's employment with the Company and/or thereafter and that Executive has a special obligation
to further the interests of the Company in relation to such Inventions. Executive shall, promptly following creation, disclose
to the Company all such Inventions and works embodying Company Intellectual Property.

 

3.2.          All
rights, title and interests in and to the Company Intellectual Property shall be solely and exclusively owned by the Company. Executive
acknowledges and agrees that any and all such Company Intellectual Property, including any marketing, advertising and promotional
materials, and other works of authorship, are “works made for hire” for purposes of the Company’s rights under
copyrights laws. Executive hereby assigns and undertakes to assign to the
Company any and all rights, title and interests he may have or acquire in such Company Intellectual Property, without any further
remuneration or compensation.       

 

3.3.          During
the period in which the Executive is employed by the Company and/or otherwise provides services to the Company, and after termination
of such period, the Executive will:

 

3.3.1.          Upon
the request of the Company, to execute all such documents, both during and after his employment, as the Company may require to
vest in the Company all right, title and interest pursuant to this Agreement;

 

3.3.2.          to
provide all such information and assistance and do all such further things as the Company may require to enable it to protect,
maintain and exploit the Company Intellectual Property to the best advantage, including (without limitation), at the Company's
request, applying for the protection of Inventions throughout the world;

 

    17

     

    

 

3.3.3.          to
assist the Company in applying for the registration of any registerable Company Intellectual Property, enable it to enforce the
Company Intellectual Property against third parties and to defend claims for infringement of third party
Intellectual Property Rights;

 

3.3.4.          not
to apply for the registration of any Company Intellectual Property in the United States or any other part of the world without
the prior written consent of the Company; and

 

3.3.5.          to
treat all Company Intellectual Property as Company's Confidential Information unless the Company has consented in writing to its
disclosure by Executive.

 

3.4.          Executive
hereby irrevocably appoint the Company as Executive's attorney in his name to sign, execute, do or deliver on Executive's behalf
any deed, document or other instrument and to use Executive name for the purpose of giving full effect to this Section 3.

 

4.   Additional
Undertakings and Representations

 

4.1.          The
Executive has not and shall not disclose to the Company or induce the Company to use any Inventions and/or confidential information
belonging to any third party.

 

4.2.          The
Executive hereby represents and warrants that he has no continuing obligations with respect to assignment or disclosure of Confidential
Information and/or Company Intellectual Property to any previous employers or other person. The Executive further certifies that
he does not claim any previous unpatented or non-published inventions or expressions, respectively, within the scope of this Agreement.

 

4.3.          The
Executive represents and warrants that the consummation by him of the transactions described herein will not result in or constitute
any of the following: a breach of any term or condition of this Agreement; a default or an event that, with notice or lapse of
time or both, would constitute a default, breach or violation of any agreement, instrument or arrangement to which the Executive
is a party or an event that would permit any third party to terminate an agreement or to accelerate the maturity of one of the
duties or obligations owed to it by the Executive.

 

4.4.          Executive
and the Company agree that it is important for any prospective employer to be aware of this Agreement, so that disputes concerning
this Agreement can be avoided in the future.  Therefore, the Executive agrees that, following termination of employment
with the Company, the Company may forward a copy of this Agreement to any future prospective or actual employer, and the Executive
releases the Company from any claimed liability or damage caused to the Executive by virtue of the Company’s act in making
that prospective or actual employer aware of this Agreement.

 

    18

     

    

 

5.   Covenant
not to Compete; Non-Solicitation.

 

5.1.          As the CEO
of the Company, the Executive had and will continue to have access to the Company’s most sensitive and commercially valuable
Confidential Information. The Executive hereby covenants that the Executive shall not, for a period of twelve (12) months after
the termination of the Executive’s employment (the "Restricted Period"), do any of the following directly
or indirectly without the prior written consent of the Company in its sole discretion:

 

5.1.1.          engage
or participate, directly or indirectly, in any business activity defined as involving C5 complement inhibitors which is in direct
competition with the business of the Company as conducted during the term of the Executive’s Employment and/or as to Executive's
knowledge is to be carried out by the Company and/or by any of its Affiliates at any time during the Restricted Period (collectively
the "Business");

 

5.1.2.          become
an employee, agent, distributor, consultant or other service provider to any person or entity engaged in a business that is competitive
with the Business of the Company;

 

5.1.3.          influence
or attempt to influence any customer or potential customer of the Company to terminate or modify any written or oral agreement
or course of dealing with the Company and/or any of its Affiliates; or

 

5.1.4.          influence
or attempt to influence any person to terminate or modify its employment, consulting, agency, distributorship or other arrangement
with the Company and/or any of its Affiliates.

 

5.2.          The
Executive acknowledges that the Executive has carefully read and considered the provisions of this Section 5. The Executive acknowledges
that the foregoing restrictions may limit the Executive’s ability to earn a livelihood in a business similar to the Company’s
business, but the Executive nevertheless acknowledges that he has received, and will receive, sufficient consideration and other
benefits in connection with the Executive’s employment with the Company to justify such restrictions, which restrictions
the Executive does not believe would prevent the Executive from earning a living in businesses that are not competitive with the
Company’s business and without otherwise violating the restrictions set forth herein.

 

    19

     

    

 

6.   General
Provisions.

 

6.1.          The
Executive acknowledges that the Company and any person, corporation, partnership or other entity affiliated with the Company will
suffer immediate and irreparable harm as a result of any violation, breach or threatened breach of this Agreement by the Executive.
The Company shall be entitled, and the Executive hereby consents to the issuance in any court of competent jurisdiction, with or
without notice, and in addition to any other remedy, including damages, which may be available at law or in equity, to temporary,
preliminary and permanent orders and injunctions, without bond or undertaking, restraining and enjoining such breach or violation
by the Executive and any other person, corporation, partnership or other entity including their officers, directors, shareholders,
employers, servants or agents who may be acting in concert with the Executive or to whom such Company Confidential Information
may have been disclosed. If the Company is successful in any legal action seeking enforcement of this Agreement or damages relating
thereto it shall be entitled to reimbursement of its out-of-pocket expenses, including reasonable legal fees and disbursements,
in connection therewith.

 

6.2.          Executive
acknowledges that:  (i) this Agreement has been specifically bargained between the parties and reviewed by Executive,
(ii) Executive has had an opportunity to obtain legal counsel to review this Agreement, and (iii) the covenants made by and duties
imposed upon Executive hereby are fair, reasonable and minimally necessary to protect the legitimate business interests of the
Company, and such covenants and duties will not place an undue burden upon Executive’s livelihood in the event of termination
of Executive’s employment by the Company and the strict enforcement of the covenants contained herein.

 

6.3.          Except
as otherwise specifically provided herein, any notice required or permitted by this Agreement shall be in writing and shall be
delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight
courier upon written verification of receipt; (iii) by telecopy or facsimile transmission upon acknowledgment of receipt of electronic
transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt.

 

		 Notices to Executive shall be sent to the last known address in Company’s records or
                                                                                    such other address as Executive may specify in writing.

 

Notices
to Company shall be sent to:

24 West
40th Street, 8th Floor

Attention:
Chairman of the Board

 

or to such other Company representative as Company may specify in writing.

 

6.4.          This
Agreement may be altered, amended or modified only in writing, signed by both of the parties hereto. 

 

    20

     

    

 

6.5.          Headings
included in this Agreement are for convenience only and are not intended to limit or expand the rights of the parties hereto.  References
to Sections herein shall mean sections of the text of this Agreement, unless otherwise indicated.

 

6.6.          This
Agreement and the rights and duties set forth herein may not be assigned by Executive without the express written consent of the
Company.  

 

6.7.          If
any court of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, then such invalidity
or unenforceability shall have no effect on the other provisions hereof, which shall remain valid, binding and enforceable and
in full force and effect, and such invalid or unenforceable provision shall be construed in a manner so as to give the maximum
valid and enforceable effect to the intent of the parties expressed therein.

 

6.8.          The
waiver by either party of the breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent
breach by either party.

 

6.9.          The
rights and obligations under this Agreement shall survive the termination of Executive's employment and/or the termination of this
Agreement, for aby reason, and shall remain in full force and effect thereafter.

 

6.10.        This
Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the law
of the State of New York, without giving effect to the conflict of law principles thereof. Any legal action or proceeding with
respect to this Agreement shall be brought in the courts of the Supreme Court of the State of New York, New York County, or of
the United States of America for the Southern District of New York. By execution and delivery of this Agreement, each of the parties
hereto accepts for itself and in respect of its property, generally and unconditionally, the non-exclusive jurisdiction of the
aforesaid courts.

 

6.11.        Jury
Waiver. ANY, ACTION, DEMAND, CLAIM, OR COUNTERCLAIM ARISING UNDER OR RELATING TO THIS AGREEMENT SHALL BE RESOLVED BY A JUDGE ALONE
AND EACH OF COMPANY AND EXECUTIVE WAIVES ANY RIGHT TO A JURY TRIAL THEREOF.

 

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first written above.

 

	GUR ROSHWALB	 	CELSUS THERAPEUTICS PLC
	 	 	 
	 	 	By: 	 
	Signature	 	Name:
	Address:	 	
        Title:

 

    21

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]